-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
The 70th! Shijiazhuang Sihua Pharmaceutical Group’s Nicardipine Hydrochloride API Has Been Approved
Category:
TIME：2025-03-05
On March 5, the nicardipine hydrochloride API developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved for registration by the National Medical Products Administration and officially listed as an API used in marketed dosage forms. With this approval, the Group now boasts a portfolio of 70 bulk and specialty APIs, including 39 under Guangxiang Pharmaceutical, gradually establishing a robust API product matrix.
According to available information, nicardipine hydrochloride, a third-generation dihydropyridine calcium channel blocker, is primarily used for the emergency management of intraoperative hypertensive crises and other hypertensive emergencies.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has aligned its strategies with national priorities and market demand, vigorously implementing an integrated “API–formulation” development approach. Leveraging the innovative collaborative model of industry–university–research–application partnerships and the pivotal role of the Provincial Technology Innovation Center for Microchannel Continuous Manufacturing, the company has actively promoted synergistic innovation in the development of specialty APIs and related formulations. As a result, its product pipeline has grown increasingly robust, its market advantages have become ever more pronounced, and its ability to accelerate corporate growth has been significantly strengthened.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
